Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy.

Guidolin, Valeria; Li, Yupeng; Jacobs, Foster C; MacMillan, Margaret L; Villalta, Peter W; Hecht, Stephen S; Balbo, Silvia

Guidolin, Valeria; Li, Yupeng; Jacobs, Foster C; MacMillan, Margaret L; Villalta, Peter W; Hecht, Stephen S; Balbo, Silvia.

Afiliação

Guidolin V; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Li Y; School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA.
Jacobs FC; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
MacMillan ML; Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA.
Villalta PW; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Hecht SS; School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA.
Balbo S; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.

Mol Ther Oncolytics ; 28: 197-210, 2023 Mar 16.

Article em En | MEDLINE | ID: mdl-36820303

Palavras-chave

DNA adduct; alkylating agents; biomarker; busulfan; mass spectrometry; precision medicine

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Mol Ther Oncolytics Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google